General Information of Drug (ID: DMWOK1D)

Drug Name
Thiomorpholine derivative 2 Drug Info
Synonyms PMID25482888-Compound-20
Cross-matching ID
TTD Drug ID
DMWOK1D

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Talabostat DM1IZ5D Constitutional neutropenia 4B00.0 Phase 3 [2]
BXCL701 DMBPUIK Prostate cancer 2C82.0 Phase 1/2 [3]
Thiomorpholine derivative 1 DMZP6KR N. A. N. A. Patented [1]
PMID20684603C24dd DMWZK9U Discovery agent N.A. Investigative [4]
1G244 DMEB8CG Discovery agent N.A. Investigative [5]
PMID15664838C18 DM93RKC Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 6 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Saxagliptin DMGXENV Type-2 diabetes 5A11 Approved [7]
Sitagliptin DMGDKXN Cystic fibrosis CA25 Approved [8]
Alogliptin DM8WI3R Type-2 diabetes 5A11 Approved [9]
Linagliptin DMWFJTR Non-insulin dependent diabetes 5A11 Approved [10]
Vildagliptin DMYN59P Type-2 diabetes 5A11 Approved [11]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride DM34TXO Type-2 diabetes 5A11 Approved [12]
Anagliptin DMJXIC9 Type-2 diabetes 5A11 Approved [13]
SaxaDapa FDC DMAPRWV Diabetic complication 5A2Y Phase 3 [14]
LC-150444 DM09RKB Type-2 diabetes 5A11 Phase 3 [15]
Dutogliptin DMM5VTA Type-2 diabetes 5A11 Phase 3 [16]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Talabostat DM1IZ5D Constitutional neutropenia 4B00.0 Phase 3 [2]
BXCL701 DMBPUIK Prostate cancer 2C82.0 Phase 1/2 [3]
Thiomorpholine derivative 1 DMZP6KR N. A. N. A. Patented [1]
PMID20684603C24dd DMWZK9U Discovery agent N.A. Investigative [4]
1G244 DMEB8CG Discovery agent N.A. Investigative [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dipeptidyl peptidase 4 (DPP-4) TTDIGC1 DPP4_HUMAN Inhibitor [1]
Dipeptidyl peptidase 8 (DPP-8) TTJGLZF DPP8_HUMAN Inhibitor [1]
Dipeptidyl peptidase 9 (DPP-9) TTNDUL7 DPP9_HUMAN Inhibitor [1]

References

1 DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma. J Immunother Cancer. 2021 Nov;9(11):e002837.
4 Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. J Med Chem. 2010 Aug 12;53(15):5620-8.
5 Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor. Biochem Pharmacol. 2009 Jul 15;78(2):203-10.
6 Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8. Bioorg Med Chem Lett. 2005 Feb 1;15(3):687-91.
7 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
8 Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38.
9 Clinical pipeline report, company report or official report of Takeda (2009).
10 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
11 Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
13 Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30.
14 Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
15 Clinical pipeline report, company report or official report of ShangHai APIs Chemical.
16 Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55.